🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05804916
Recruiting Phase 2/3

Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer

NCT05804916 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Phase 2/3
Started
2022-04-01
Last updated
2023-04-07

Condition(s) studied

Breast CancerOptical Surface Monitoring TechnologyLarge-segment Radiotherapy

Investigational drug(s) / intervention(s)

Surface Guided Radiation Therapy (SGRT)

Surface Guided Radiation Therapy (SGRT): SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection

Study summary

This study is a single-center,blinded, efficacious, phase III randomized clinical trial initiated by investigators. The primary objective is to investigate the use of Surface Guided Radiation Therapy (SGRT) in combination with Deep Inspiration Breath Hold (DIBH) technique for left breast cancer treatment, compared to traditional laser alignment with free breathing treatment. This approach offers superior positioning accuracy and improved heart protection without any increase in radiation or adverse reactions.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who have undergone breast-conserving surgery or modified radical mastectomy for left breast cancer; 2. Planned whole-breast ± supraclavicular region, chest wall ± supraclavicular region radiotherapy; 3. Able to perform deep inspiration breath-hold technique with breath-holding time \>35s and can repeat it continuously for more than 6 times; 4. Patients who have not received neoadjuvant chemotherapy or breast reconstruction surgery; 5. No active heart disease, myocardial infarction, congestive heart failure or other cardiac diseases at baseline; 6. Patients are fully voluntary and able to sign the informed consent form 30 days before enrollment. Exclusion Criteria: 1. Bilateral breast cancer; 2. No pathological diagnosis; 3. Remote metastasis; 4. Receiving neoadjuvant chemotherapy or breast reconstruction; 5. Have received mediastinal radiotherapy in the past; 6. Previous history of abdominal or pelvic radiotherapy; 7. Previous or secondary primary malignant tumor; 8. Serious cardiac insufficiency; Myocardial infarction or uncorrected unstable arrhythmia or uncorrected unstable angina pectoris occurred in the last 3 months; Pericardial disease.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting

More Peking Union Medical College Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05804916 on ClinicalTrials.gov ↗ ← All trials in China